u/Acceptable_Ratio7831

[ Removed by Reddit on account of violating the content policy. ]

Compiled a FAQ for newer members of the research community. Sharing here for critique/additions:

1. DELIVERY: Match to compound. Injectable, intranasal, and oral all have different bioavailability profiles — not all peptides work the same way via oral.
2. SOURCING: Demand lot-specific COA with HPLC + mass spec from accredited labs. Generic COAs are meaningless.
3. MECHANISM FIRST: Understand why before you research what. Match the compound to the biological system you're studying.
4. EVIDENCE TIERS: Know the difference between extensive animal data (BPC-157), solid human trials (CJC-1295), and preclinical-only (MOTS-c, Epithalon).
5. CYCLING: Not all peptides run continuously. Epithalon is cycled. GHK-Cu can run continuously. Understand the rationale for each.

What would you add? What do newer researchers consistently get wrong?

(I supply research peptides — DM for sourcing.)

⚠️ Research only.

The sourcing quality conversation doesn't happen enough in this community. Given that a 2018 analysis found purity as low as 5–75% in some research peptides, with contaminants well above reasonable thresholds, I think it should.

My non-negotiables for sourcing:

1. Lot-specific COA (not a reused template)
2. HPLC + mass spec identity and purity confirmation
3. Third-party accredited lab (ISO/IEC 17025 preferred)
4. Batch traceability

What are yours? And what red flags have you encountered from suppliers?

(I supply research peptides and hold ourselves to the above standard — happy to discuss or share documentation.)

⚠️ Research only.

After months in the literature, here's how I've organized my current research stack by system:

RECOVERY: BPC-157 + TB-500 (localized angiogenic + systemic cell migration — complementary mechanisms)
GH AXIS: CJC-1295 No DAC + Ipamorelin (pulsatile stimulation, cortisol/prolactin neutral)
LONGEVITY: MOTS-c + Epithalon (mitochondrial signaling + telomerase pathway)
CELLULAR: GHK-Cu (ECM remodeling, antioxidant, collagen)
METABOLIC: AOD-9604 (fat fragment, no insulin effects)
COGNITIVE: Semax + Selank (BDNF up, GABA-anxiolytic, no sedation)
INFLAMMATION: KPV (cytokine modulation, gut barrier)

Design principle: target different biological systems, not the same one twice. Would love mechanistic critique or suggestions.

(I supply all of these as research compounds — DM for sourcing.)

⚠️ Research only.

Working through the mechanistic rationale for stacking Semax and Selank together. The push/pull logic makes intuitive sense — Semax for cognitive uplift, Selank for anxiolytic effect without sedation. But I want to understand if there's actual mechanistic synergy or if they're just additive.

Semax appears to work primarily through BDNF/ACTH pathways. Selank through GABA modulation and enkephalin effects. These seem genuinely complementary rather than redundant.

Curious what the community thinks:

- Does the GABA modulation from Selank blunt any of the Semax cognitive effect?

- Any thoughts on sequential vs. simultaneous administration in research models?

(I supply both — DM for sourcing.)

⚠️ Research only.

Working on the mechanistic rationale for the BPC-157/TB-500 stack. The complementary pathways make sense — but the half-life difference has me thinking about protocol design.

BPC-157 has a shorter half-life and appears to work locally. TB-500 distributes more widely and persists longer. Does that suggest different dosing frequencies make more sense than running them on the same schedule?

Also interested in thoughts on administration site — with TB-500's systemic distribution, does location matter less vs. BPC-157 where proximity to target tissue seems more relevant?

(I supply both — DM for sourcing.)

⚠️ Research only.

Spent the week going through KPV literature. The alpha-MSH fragment mechanism is interesting — particularly the MC1R pathway interaction for inflammation modulation.

The gut data is compelling for IBD-adjacent research. Curious whether the community sees more signal in the oral vs. systemic delivery data.

Also wondering about KPV + BPC-157 stacking logic — both have gut-related research profiles but different mechanisms. Anyone looked at that combination?

(I carry KPV as a research compound — DM for sourcing info.)

⚠️ Research only.

Going through the Khavinson Institute research on Epithalon. The animal longevity data showing extended median/maximum lifespan is compelling.

Questions for the community:

- Is the telomerase activation direct, or upstream epigenetic signaling?

- Thoughts on the limited human data from Russian clinical research (early 2000s)?

- Protocol cycling rationale — why 10–20 day cycles vs. continuous?

Also interested in thoughts on the Epithalon + MOTS-c combo from a cellular aging perspective.

(I supply Epithalon as a research compound — DM for sourcing.)

⚠️ Research only. Not medical advice.

Going deep on GHK-Cu this week. The copper binding changes its tissue interaction profile vs. most peptides — curious what the community has found on delivery mechanisms.

My read: topical shows strong data for dermal endpoints, but the systemic wound healing and antioxidant data seems to require different delivery approaches.

Also interested in the gene expression angle — the ECM remodeling and MMP regulation data is fascinating.

Anyone tracking quantitative markers (collagen density, etc.) across a research period?

(I carry GHK-Cu — DM for sourcing info if needed.)

⚠️ Research only.

Working through the CJC-1295 literature and the No DAC vs DAC question keeps coming up.

My read: No DAC mimics pulsatile GH release more closely, while DAC provides a longer half-life but flatter GH curve. For mimicking natural physiology, No DAC + Ipamorelin seems to be the cleaner research approach.

Curious what the community has found:

- Protocol timing (2x/day vs. pre-sleep only?)

- Any data on Ipamorelin's cortisol/prolactin neutrality compared to other GHRPs?

- Thoughts on saturation dosing concepts?

(I supply research-grade CJC-1295/Ipamorelin — DM for sourcing if needed.)

⚠️ Research only. Not medical advice.

Been deep in BPC-157 research lately — specifically the gut lining and intestinal anastomosis data. The animal studies on barrier function restoration are compelling.

Curious what protocols others are working with:

- Dosing frequency (daily vs. every other day)?

- Oral vs. injectable in your research models?

- Any markers you're tracking to measure change?

Happy to share what I've found. (I also supply research-grade BPC-157 — DM if you need sourcing info, not the point of this post.)

⚠️ Research purposes only. Not medical advice.